CYCN Logo

Cyclerion Therapeutics, Inc. (CYCN) 

NASDAQ$2.55+0.02 (0.79%)
Market Cap
$6.86M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
546 of 924
Rank in Industry
319 of 527

CYCN Insider Trading Activity

CYCN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$555,1081100

Related Transactions

Slate Path Capital LP10 percent owner0$01$555,108$-555,108

About Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also â€¦

Insider Activity of Cyclerion Therapeutics, Inc.

Over the last 12 months, insiders at Cyclerion Therapeutics, Inc. have bought $0 and sold $555,108 worth of Cyclerion Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cyclerion Therapeutics, Inc. have bought $4.37M and sold $214,373 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 961,538 shares for transaction amount of $3M was made by Slate Path Capital LP (10 percent owner) on 2021‑06‑03.

List of Insider Buy and Sell Transactions, Cyclerion Therapeutics, Inc.

2024-11-21SaleSlate Path Capital LP10 percent owner
357,880
11.132%
$1.55$555,108+111.97%
2023-08-09SaleMCGUIRE TERRANCEdirector
8
0.0003%
$3.40$27-10.40%
2021-06-03PurchaseSlate Path Capital LP10 percent owner
961,538
0.1301%
$3.12$3M-39.01%
2021-06-03PurchaseHecht Peter MChief Executive Officer
823,170
0.1171%
$3.28$2.7M-39.01%
2021-06-03PurchaseMCGUIRE TERRANCEdirector
96,153
0.013%
$3.12$299,997-39.01%
2021-05-06PurchaseHecht Peter MChief Executive Officer
302,000
0.0413%
$2.43$733,860+6.43%
2021-05-05PurchaseHecht Peter MChief Executive Officer
398,001
0.0553%
$2.53$1.01M+3.92%
2021-05-04PurchaseHecht Peter MChief Executive Officer
300,000
0.0415%
$2.29$687,000+14.22%
2021-02-25SaleWright Christopher IChief Medical Officer
2,637
0.0004%
$3.99$10,522-24.61%
2021-02-25SaleGjino AnjezaChief Financial Officer
1,824
0.0003%
$4.00$7,296-24.61%
2020-12-28SaleCurrie Mark GPresident and CSO
20,107
0.0032%
$3.01$60,522+3.68%
2020-11-09PurchaseBusch AndreasChief Innovation Officer
125,000
0.0199%
$2.53$316,250+27.42%
2020-11-06SaleHuyett WilliamChief Financial Officer
3,827
0.0006%
$2.52$9,644+27.42%
2020-02-21SaleHuyett WilliamChief Financial Officer
3,559
0.0007%
$5.12$18,222-16.49%
2019-12-30SaleCurrie Mark GPresident
25,000
0.0839%
$2.48$62,000+42.59%
2019-12-27SaleCurrie Mark GPresident
25,000
0.0917%
$2.55$63,750+51.97%
2019-11-15PurchaseBusch AndreasChief Innovation Officer
125,000
0.4616%
$1.82$227,500+114.44%
2019-11-08SaleHuyett WilliamChief Financial Officer
3,922
0.0155%
$2.05$8,040+103.16%
2019-04-08PurchaseSCHULMAN AMY Wdirector
626,117
0.1105%
$16.00$10.02M-46.83%
2019-04-08PurchaseMCGUIRE TERRANCEdirector
626,117
0.1105%
$16.00$10.02M-46.83%
Total: 21
*Gray background shows transactions not older than one year

Insider Historical Profitability

6.18%
Slate Path Capital LP10 percent owner
0
0%
$011<0.0001%
Hecht Peter MChief Executive Officer
2047698
75.558%
$5.18M40<0.0001%
SCHULMAN AMY Wdirector
604482
22.3048%
$1.53M10
Busch AndreasChief Innovation Officer
254704
9.3983%
$644,401.1220+70.93%
Currie Mark GPresident and CSO
251648
9.2856%
$636,669.4413
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$1,226,605
43
-21.28%
$7.98M
$523,320
24
94.37%
$7.01M
$746,223
23
-7.24%
$9.07M
$31,129
22
-11.96%
$6.19M
$1,080,165
17
-6.62%
$7.91M

CYCN Institutional Investors: Active Positions

Increased Positions7+38.89%21,632+2.07%
Decreased Positions5-27.78%682,328-65.44%
New Positions5New10,747New
Sold Out Positions2Sold Out527,340Sold Out
Total Postitions20+11.11%381,943-63.37%

CYCN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Tyndall Capital Partners L P$417.005.49%164,77700%2024-12-31
Siren, L.L.C.$294.003.87%116,15500%2024-12-31
Geode Capital Management, Llc$81.001.06%31,820-2,088-6.16%2024-12-31
Vanguard Group Inc$59.000.78%23,49000%2024-12-31
Blackrock, Inc.$42.000.56%16,79700%2024-12-31
Renaissance Technologies Llc$27.000.35%10,611+10,611New2024-12-31
Ubs Group Ag$24.000.32%9,667+9,522+6,566.9%2024-12-31
Fmr Llc$12.000.16%4,740-152,896-96.99%2024-12-31
Tower Research Capital Llc (Trc)$6.000.08%2,441+1,363+126.44%2024-12-31
Morgan Stanley$2.000.02%64900%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.